CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® for the treatment of IgA Nephropathy

Vifor International AG (CSL Vifor) Austria Belgium Czech Republic Denmark Finland France Germany Greece Ireland Italy Luxembourg Netherlands Norway Poland Portugal Russia Spain Sweden United Kingdom California Switzerland Pennsylvania